Background: Testicular cancer treatment has become standardized in the 1980s involving radiotherapy preferentially for seminoma and chemotherapy for nonseminoma. The late effects of these therapeutic practices have not been properly evaluated because of the relatively short time since their application.
introduction
The incidence of testicular cancer has increased in many countries, including Sweden, for unknown reasons and it is the most frequently occurring cancer in young white men [1, 2] . The known risk factors for testicular cancer include undescended testis (cryptorchidism), in utero hormonal exposures, testicular dysfunction, perinatal factors, prior history of cancer in one testis (the opposite testis is at increased risk) and family history of testicular cancer [2, 3] . The firstgeneration immigrants to Sweden and Denmark show generally a decreased risk of testicular cancer compared with the natives, but this difference tends to disappear in the next generation born in the new host country, indicating a role for environmental factors [4] [5] [6] [7] [8] . Testicular cancers are predominantly germ-cell tumors of two main types, seminomas and nonseminomas; the later include teratomas, with somatic differentiation, and undifferentiated embryonal tumors [3] . However, about one half of the germ-cell tumors of the testis contain multiple histological types and the remainder contains a single histological type [3] . Similar incidence trends in seminoma and nonseminoma have been indicated to imply sharing of etiological factors between the histological types [9] .
Survival in testicular cancer is high with a 10-year relative survival of >95% for both seminoma and nonseminoma in Sweden since the current treatment and diagnostic modalities were consolidated [10] . The treatment depends on whether the disease is localized or metastatic, including orchiectomy and primarily radiation for seminoma and BEP (bleomycin, etoposide and cisplatin) for nonseminoma and mixed tumors [11] [12] [13] . For metastatic seminoma, the radiation therapy is intensified and targeted into wider fields, and BEP may be administered; for nonseminoma and mixed tumors, more cycles of BEP are administered. As these therapeutic principles with some variation were taken to use in the 1980s, the maximal follow-up times of the surviving patients are barely exceeding two decades. Previous large studies on survivors of testicular cancer reported an increased risk of several second malignancies but, as the follow-up times ended at or before the year 2000, the number of patients treated with the current protocols was small and no second testicular cancer were included [14] [15] [16] . For example, the multicenter study of 13 cancer registries with 29 500 testicular cancer patients included only 491 second cancers (27%) in testicular cancer patients diagnosed since 1980 [16] . In that study, Swedish patients diagnosed from 1961 to 1998 constituted 16.3% of the study population. Considering that the effects of radiotherapy and chemotherapy may extend to at least four decades, it is important that testicular cancers are followed for the effects of the treatments adopted in the 1980s [14] [15] [16] [17] [18] [19] [20] .
We conducted a study among 5533 survivors of testicular cancer on the basis of Swedish Family-Cancer Database for which the cancer data were retrieved from the nationwide Cancer Registry. The follow-up was started in 1980 and carried on through 2006 covering the time of relatively standard treatment protocols for the two main types of testicular cancers. All cancers including second testicular cancers were included in the follow-up.
patients and methods
The Swedish Family-Cancer Database was first assembled from the national databases in 1996 and since then it has been periodically updated most recently in 2008 [21, 22] . The database contains those born in Sweden since 1932 with their biological parents, totaling >11.8 million persons and >1.2 million tumor notifications. Cancer cases were retrieved from the Swedish Cancer Registry, which relies on separate compulsory notifications from clinicians who diagnosed the neoplasms and pathologists/cytologists. All registered testicular cancers cases are histologically verified. An ad hoc study on the diagnostic accuracy of second neoplasms in the Swedish Cancer Registry found 98% to be correctly classified [23] . In the present analyses, 5533 patients with first primary testicular cancer were followed from diagnosis after 1 January 1980 until death, detection of a second primary cancer, emigration or 31 December 2006, whichever came first. Second cancers were classified as such by the Cancer Registry, including synchronous tumors. The incidences of second malignancies among testicular cancer patients were compared with the rates in the general Swedish population by standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), adjusting for covariates age (5 year bands), sex, socioeconomic index (six groups), region (four groups) and calendar year (1961-1965, 1965-1969, . , 2000-2004) . Separate analyses were carried out according to age at testicular cancer diagnosis (20-39, 40-49, 50-59, 60-69 and 70+ years), time since testicular cancer diagnosis (0-10, 11-20, 21-30 and 31+ years) and period of testicular cancer diagnosis (1961-2004 and 1975-2004) . SIR applies indirect standardization, which is particularly suitable for cells with small numbers of subjects [24] [25] [26] . In this method, the observed numbers of cases are divided by the expected numbers of cases, calculated from the whole background population of 11.8 million. CIs (95%) were calculated assuming a Poisson distribution. SAS software version 9.1 was used for data analysis.
results
The Family-Cancer Database included 3001 seminomas and 2532 nonseminomas diagnosed since the year 1980. Table 1 shows SIRs for a total of 370 (6.7% of all patients) second (26) ; for nonseminoma, the difference was small (13 versus 12). After both seminoma and nonseminoma, the SIRs of all discordant subsequent cancers were higher when testicular cancer was diagnosed before age 30, i.e. 2.71 versus 1.91 after seminoma and 3.78 versus 1.79 after nonseminoma. All significant increases after seminoma diagnosed after age 29 years were in line with Table 1 . For subsequent cancers after nonseminoma diagnosed before age 30, high SIRs were recorded for kidney (23.26) , bladder (8.59) and connective tissue (11.59) cancers. Unfortunately, the body parts of the connective tissue tumors were not specified.
In Table 3 , the effect of follow-up was analyzed. The risk for second testicular cancer is very high within the year of the initial diagnosis but it remained elevated even 10-19 years later (14.10 after seminoma and 12.02 after nonseminoma). Discordant cancers diagnosed within the year of testicular cancer diagnosis showed the highest SIRs but these constituted 
discussion
In studies of subsequent cancers, it is often debated whether synchronous discordant cancers should be included because they may be affected by lead time bias, i.e. they are diagnosed earlier than in cases without diagnosis of the first cancer. In the Swedish Cancer Registry, 99% of the diagnoses are histologically or cytologically verified [27] . Thus, excluding synchronous cancers would cause a deficit in subsequent observation periods. In the present study, we included all cancers diagnosed after testicular cancer. The risks for many cancers were high in the first year after testicular cancer diagnosis but the case numbers corresponded to £15% of all discordant cases. The risk of second testicular cancer is well known but many recent large studies have not included concordant tumors because many cancer registries do not record them. A small clinical study adhering to the current treatment protocol found 2.5% (5.2% after pure seminoma and 1.2% after nonseminoma) of the testicular cancer patients to be diagnosed with a contralateral tumor [28] . The present figures for second testicular cancer were 2.1% after seminoma and 1.3% after nonseminoma; however, a proportion of cases lacked data on laterality. The SIRs for second testicular cancer diagnosed within 1 year of the initial diagnosis were 130 after seminoma and 63 after nonseminoma. After seminoma, the SIRs remained at 15 up to 20 years of follow-up; after nonseminoma, they varied between 7 and 12. The initial very high risks were obviously contributed by lead time bias but even the subsequent risks were high enough to warrant alertness in the patient follow-up. Therapy is likely to contribute to the high risks but even other factors such as shared risk factors and individual susceptibility found for many types of multiple cancers may be present [29, 30] .
Also nontesticular second tumors were more common (6.4%) after seminoma than after nonseminoma (3.2%). In our earlier Swedish study, on cases diagnosed from 1958 to 1996, the percentages were 8.4 and 3.4, respectively [31] . In the present study, the SIRs for all nontesticular tumors were 1.93 after seminoma and 2.14 after nonseminoma. Risks for second cancer were high if nonseminoma was diagnosed before age 30 (3.78 compared with 2.71 after seminoma) and they decreased for patients treated at an older age (1.79 after nonseminoma and 1.91 after seminoma). The case numbers were limited to make definite statements about the spectrum of individual cancer sites after seminoma and nonseminoma. However, gastrointestinal tract cancers occurred mainly after seminoma and bladder cancers occurred after nonseminoma. The risk of bladder cancer was 8.59 and that of connective tissue cancer was 11.59 in patients treated for nonseminoma before age 30. Other tumors that preferentially occurred in nonseminoma patients where squamous cell skin cancer and chronic myeloid leukemia. Acute and chronic myeloid leukemias have previously been associated with chemotherapyrelated late effects of testicular cancer treatment while gastrointestinal tract tumors have been associated with supradiaphragmatic radiotherapy [14, 16, 32, 33] . Bladder, skin and connective tissue cancers can all be induced by radiation therapy and it is also possible that they are induced by chemotherapy [20] . Active ingredients of the BEP regimen are likely to be excreted in bladder with a possibility to transform bladder epithelial cells. The possible association of bladder cancer with therapy for nonseminoma needs to be considered in future studies. 
